Amgenvs.United Therapeutics
AMGN vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 9.6× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.4 vs 25.2); year to date, Amgen leads (+26.2% vs +9.3%).
Side by side
| AMGN | UTHR | |
|---|---|---|
| Market cap | $220B | $22.9B |
| Price | $414.87 | $549.16 |
| Today | +1.8% | +3.1% |
| Return YTD | +26.2% | +9.3% |
| Return 1Y | +39.8% | +18.7% |
| Since June 26, 2026 | +15.8% | +1.2% |
| P/E | 25.2 | 17.4 |
| P/S | 5.8 | 7.2 |
| P/B | 18.8 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More AMGN & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.